Biochemical relationship between leiomyosarcoma and peroxiredoxin-6 expression level: Clinical implications

Herkiloglu D., Gokce S., Kaygusuz E. I., Cevik O., Ahmad S.

Indian Journal of Biochemistry and Biophysics, vol.59, no.5, pp.552-557, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 5
  • Publication Date: 2022
  • Journal Name: Indian Journal of Biochemistry and Biophysics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, Directory of Open Access Journals
  • Page Numbers: pp.552-557
  • Keywords: Biomarker, Clinical relevance, Histopathology, Leomyosarcoma, Myoma, Peroxiredoxin-6, Prognosis
  • İstanbul Yeni Yüzyıl University Affiliated: Yes

Abstract

Uterine leiomyosarcomas are tumors with a heterogeneous genetic profiles that respond very poorly to cytotoxic chemotherapy with aggressive progression. We aimed to show the status of peroxiredoxin 6 as a biomarker in leiomyosarcoma progression.Study included 12 patients diagnosed with "leiomyosarcoma" and 13 patients diagnosed with "myoma" (as control) after histopathological examinations of clinical samples. Peroxiredoxin-6 gene expression and protein levels were evaluated on the tumor preparations (blocks) utilizing ELISA and PCR methods.Peroxiredoxin-6 protein was mainly localized in the cytoplasm of leiomyosarcoma cells, and the expression of peroxiredoxin-6 was significantly increased in cancerous tissues compared to normal myoma tissues (3.33±1.7 vs. 2.03±1.07fold change; P= 0.031). Peroxiredoxin-6 tissue protein levels were also significantly higher in leiomyosarcoma cases (100.54±66.86 vs. 183.72±64.54 pg/µg protein; P= 0.005). Our findings demonstrate that peroxiredoxin-6 plays a vital role in the emergence and development of leiomyosarcoma and that peroxiredoxin-6 level assessments can be used as a biomarker in guiding better prognosis andtreatment plans while managing leiomyosarcoma.